CR-CP Life Science Fund
Asia, Hong Kong Island, Hong Kong, Wan Chai'/%3e%3cuse xlink:href='%23a' transform='rotate(144 450 300)'/%3e%3cuse xlink:href='%23a' transform='rotate(216 450 300)'/%3e%3cuse xlink:href='%23a' transform='rotate(288 450 300)'/%3e%3c/svg%3e)
Description
CR-CP Life Science Fund is a joint venture set up by China Resources Group and Charoen Pokphand Group.
Investor Profile
CR-CP Life Science Fund has backed more than 10 startups, with 0 new investments in the last 12 months alone. The firm has led 3 rounds, about 30% of its total and boasts 5 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series B, Series C, Series E rounds (top funding stages).
- Majority of deals are located in China, Belgium, Singapore.
- Strong thematic focus on Biotechnology, Health Care, Medical.
Stage Focus
- Series B (70%)
- Series C (20%)
- Series E (10%)
Country Focus
- China (50%)
'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)
- Belgium (20%)
- Singapore (10%)
'/%3e%3cuse xlink:href='%23a' transform='translate(288.889 -214.211)'/%3e%3cuse xlink:href='%23a' transform='translate(108 342.749)'/%3e%3cuse xlink:href='%23a' transform='translate(469.189 342.749)'/%3e%3c/svg%3e)
- United Kingdom (10%)
'%3e%3cpath fill='%23012169' d='M0 0v30h60V0z'/%3e%3cpath stroke='%23fff' stroke-width='6' d='m0 0 60 30m0-30L0 30'/%3e%3cpath stroke='%23C8102E' stroke-width='4' d='m0 0 60 30m0-30L0 30' clip-path='url(%23b)'/%3e%3cpath stroke='%23fff' stroke-width='10' d='M30 0v30M0 15h60'/%3e%3cpath stroke='%23C8102E' stroke-width='6' d='M30 0v30M0 15h60'/%3e%3c/g%3e%3c/svg%3e)
- Israel (10%)
Industry Focus
- Biotechnology
- Health Care
- Medical
- Therapeutics
- Biopharma
- Big Data
- Oncology
- Life Science
- Laser
- Medical Device
FAQ
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
